About: Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2012 (uk) im Februar 2012 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57268573-82480EA0-86B6-4776-A34F-3D51CD8F28B9
publication date	2012-01-18 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57268573-0C20DA3F-7DEC-4D28-9694-E1FB1B4D6A6E
language of work or name	English
author name string	wds:Q57268573-228A5485-5BF9-4773-9087-78F863ABD3E1 wds:Q57268573-2FA5CDA2-C223-4698-9460-EC0C04E35E3F wds:Q57268573-5BD7337F-0F67-4F52-8854-B642EA3C7925 wds:Q57268573-BACDB608-E7B2-40BF-8EE8-60B8074AC652 wds:Q57268573-EC44E63D-65A4-4635-9823-2A8789A9942F wds:Q57268573-F6288437-6347-46CF-9C9E-7EA1488E26D2
author name string	Jadwiga Marcinkiewicz Maxime Denis Claude Lazure Dany Gauthier Ahmed Zaid Steve Poirier
rdfs:label	Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (en) Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (nl)
skos:prefLabel	Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (en) Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (nl)
name	Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (en) Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice (nl)
author	wds:Q57268573-078CF9E1-87A3-4768-BC35-F9D750300F91 wds:Q57268573-CDDD1FDE-34A4-429C-8832-C3817ABDB1A9
author	Nabil Seidah Annik Prat
title	wds:Q57268573-66D54383-003E-40A0-A741-52F5D4CDA433
title	Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice (en)
page(s)	wds:Q57268573-40F70C91-0CB3-4DD4-8D83-7A7908F284BB
page(s)	894-901
instance of	wds:Q57268573-CCF685C5-1BE6-48E9-A78B-82420C623367
instance of	scholarly article
main subject	wds:Q57268573-0368CBD8-5FB3-46D2-9B0A-3D674BB56691
main subject	atherosclerosis
PubMed ID	wds:Q57268573-5549849E-B640-4A3D-8244-03FF0CAC5B80
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22261195
PubMed ID	22261195
published in	wds:Q57268573-09D87912-0404-4B26-ABF6-CC06A454FC22
published in	Circulation
issue	wds:Q57268573-E6E7E5EB-2C3D-47A6-AA9C-16A0F925D7DD
volume	wds:Q57268573-B5FD4A7D-233B-413E-A8AE-5933BE670C13
issue	7
volume	125
DOI	wds:Q57268573-E6432B24-E0D9-43E6-9372-E0F8F78314BC
DOI	http://dx.doi.org/10.1161/CIRCULATIONAHA.111.057406
DOI	10.1161/CIRCULATIONAHA.111.057406
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57268573
is cites work of	The biology and therapeutic targeting of the proprotein convertases Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Local effects of human PCSK9 on the atherosclerotic lesion FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions The PCSK9 decade PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol Effects of LDL Receptor Modulation on Lymphatic Function Identification of CAD candidate genes in GWAS loci and their expression in vascular cells The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway Anti-PCSK9 therapies for the treatment of hypercholesterolemia Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin PCSK9 Inhibitors: potential in cardiovascular therapeutics Regression of atherosclerosis Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects PCSK9 inhibitors in the prevention of cardiovascular disease Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases PCSK9 as a therapeutic target for cardiovascular disease Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications New drugs for treating dyslipidemia: beyond statins Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study PCSK9 induces a pro-inflammatory response in macrophages. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids Hepatic overexpression of the prodomain of furin lessens progression of atherosclerosis and reduces vascular remodeling in response to injury Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering PCSK9 and Atherosclerosis - Lipids and Beyond PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction PCSK9 inhibitors: A new era of lipid lowering therapy. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software